Drug
Rivastigmine clinical trials
Also written Exelon and ENA713.
Keep track of what changes. Save the Rivastigmine studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
61 studies that test it; most in 2008 (9)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2002 | 4 |
| 2003 | 5 |
| 2004 | 2 |
| 2006 | 3 |
| 2007 | 4 |
| 2008 | 9 |
| 2009 | 7 |
| 2011 | 7 |
| 2012 | 3 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 2 |
| 2018 | 1 |
| 2019 | 4 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 27 · Other 35
Novartis (13) · Novartis Pharmaceuticals (12) · University of Maryland, Baltimore (2) · Baylor College of Medicine (2) · Dr. Reddy's Laboratories Limited (2) · Washington University School of Medicine (2) · UMC Utrecht (2) · Alexandria University (1)
Often tested with
Tested in the same studies.
Memantine (4) · Melatonin (2) · Atomoxetine (2) · Reboxetine (2) · Diphenhydramine (2) · Tranylcypromine (2) · Methylphenidate (2) · Haloperidol (2)
Related medicines
As reviewed, each with the page that says it.
- One of Cholinesterase Inhibitors source
- One of Neuroprotective Agents source
Studies
Open first, then newest update. How each study uses Rivastigmine is read from its arms, and is right about nine times in ten.
Testing it · 62
- Rivastigmine for Antimuscarinic DeliriumRecruitingPhase 2Washington University School of MedicineNCT06382649Written as Rivastigmine
- Rivastigmine as an Antidote for Clozapine-induced Central Nervous System Depression and DeliriumCompletedPhase 4Alexandria UniversityNCT07545382Written as Rivastigmine
- Rivastigmine to Prevent Recurrence of Antimuscarinic DeliriumSuspendedPhase 2Washington University School of MedicineNCT06399679Written as Rivastigmine
- A Phase IV Study to Evaluate Safety, Tolerability and Effectiveness of Rivastigmine Patch 15cm2 in Patients With Severe Dementia of the Alzheimer's Type.CompletedPhase 4Novartis PharmaceuticalsNCT02989402Written as Rivastigmine
- Cholinergic Neurotransmission in Mobility and Cognition in Parkinson DiseaseCompletedPhase 4University of Maryland, BaltimoreNCT03840837Written as Rivastigmine transdermal patch
- Efficacy of RIVAstigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear PalsyCompletedPhase 3Assistance Publique Hopitaux De MarseilleNCT02839642Written as Rivastigmine
- Effect of Heat on Rivastigmine TDS ProductsCompletedEarly Phase 1University of Maryland, BaltimoreNCT03915626Written as Rivastigmine (RLD) transdermal patch
- Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage AD Having Coexisting svCVDCompletedPhase 4National Neuroscience InstituteNCT02444637Written as Rivastigmine
- Rivastigmine Patch Compared to Melatonin Patch in Prevention of Postoperative DeliriumCompletedPhase 1/2Ain Shams UniversityNCT04189666Written as Rivastigmine Transdermal System [Exelon]
- Cognitive Decline in Non-demented PDCompletedPhase 4Oregon Health and Science UniversityNCT01340885Written as Exelon
- Noradrenaline, Acetylcholine and Dynamic Learning in Healthy HumansCompletedNot applicableUniversity of OxfordNCT03957174Written as Rivastigmine
- NextStep:Study to Evaluate Safety,Efficacy & Tolerability of Rivastigmine Patch in Mild to Moderate Alzheimer's Patients.CompletedPhase 4Novartis PharmaceuticalsNCT02703636Written as Rivastigmine Patch
- Cholinesterase Inhibitors to Slow Progression of Visual Hallucinations in Parkinson&Apos;s DiseaseTerminatedPhase 4Amsterdam UMC, location VUmcNCT01856738Written as Rivastigmine
- Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's DementiaCompletedPhase 4Novartis PharmaceuticalsNCT01585272Written as ENA713
- Methylphenidate, Rivastigmine or Haloperidol in Hypoactive Delirium in Intensive Care PatientsTerminatedPhase 3UMC UtrechtNCT00599287Written as Rivastigmine
- Pharmacovigilance in Gerontopsychiatric PatientsTerminatedPhase 3Hannover Medical SchoolNCT02374567Written as Rivastigmine
- Rivastigmine Patch in Veterans With Cognitive Impairment Following TBICompletedPhase 3VA Office of Research and DevelopmentNCT01670526Written as Rivastigmine Transdermal Patch
- Cognitive Changes in Alzheimer's Disease Patients Associated With or Without White Matter Changes After RivastigmineCompletedNot applicableDong-A UniversityNCT01380288Written as rivastigmine patch
- Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's DiseaseCompletedPhase 3Novartis PharmaceuticalsNCT00099242Written as rivastigmine transdermal patch
- Mild Cognitive Impairment in Parkinson's DiseaseCompletedPhase 4University of PennsylvaniaNCT01519271Written as Exelon Patch (rivastigmine transdermal system)
See all 62 studies that test Rivastigmine →
Given in every arm · 4 — Rivastigmine is usual care beside what is tested
- Safety and Efficacy of AR1005 in Patients with Lewy Body DiseaseRecruitingPhase 2Yonsei UniversityNCT06537076Written as Rivastigmine 3 mg
- A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease TherapyCompletedPhase 2Hoffmann-La RocheNCT01677754Written as Rivastigmine
- Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's DiseaseCompletedPhase 1FORUM Pharmaceuticals IncNCT00766363Written as Rivastigmine
- Effects of Exercise and Rivastigmine on Quality of Life of Alzheimer's Disease PatientsCompletedPhase 3Federal University of BahiaNCT01183806Written as Rivastigmine
As the comparator · 7 — what is tested is compared with Rivastigmine
- Rivastigmine Transdermal Patches Bioequivalence and Adhesion AssessmentCompletedPhase 1Zodiac Produtos Farmaceuticos S.A.NCT07464340Written as Exelon® 9.5 mg/24 h
- Rivastigmine Bioequivalence Trial With Multiple Applications of Transdermal Patches (9.5 mg/24 h)CompletedPhase 1SocraTec R&D GmbHNCT05883124Written as Exelon® 9.5 mg/24 h
- Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (13.3mg/24h)CompletedPhase 1Luye Pharma Group Ltd.NCT05853341Written as Exelon® 13.3 mg/24 h
- Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (9.5mg/24h)CompletedPhase 1SocraTec R&D GmbHNCT03659435Written as Exelon® 9.5 mg/24 h
- Rivastigmine BA Trial With Multiple Application of Transdermal Patches, Adaptation and Tapering PhaseCompletedPhase 1SocraTec R&D GmbHNCT03573050Written as Exelon® 13.3 mg/24 hours transdermal patch
- Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)CompletedPhase 3Novartis PharmaceuticalsNCT01614886Written as ENA713
- Efficacy and Safety of Two Pharmacologic Strategies on Neurocognitive Impairment in HIV Infection. The TRIANT-TE StudyCompletedPhase 4Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la CienciaNCT01348282Written as Rivastigmine
Codes
What other systems call Rivastigmine · ClinicalTrials.gg INT006547
- MeSH (NLM) D000068836RivastigmineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) PKI06M3IW0RIVASTIGMINEConfirmed FDA, NLM, Wikidata
- RxNorm 183379Confirmed FDA, Wikidata
- Wikidata Q411887rivastigmineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C66519RivastigmineOne source FDA
- DrugBank DB00989One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000068836 | Rivastigmine | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | PKI06M3IW0 | RIVASTIGMINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 183379 | — | Confirmed FDA, Wikidata |
| Wikidata | Q411887 | rivastigmine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C66519 | Rivastigmine | One source FDA |
| DrugBank | DB00989 | — | One source Wikidata |
Also registered as rivastigmine tartrate (UNII 9IY2357JPE · RxNorm 994808).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.